Virtus Fund Advisers’s Ultragenyx Pharmaceutical RARE Stock Holding History

Virtus Fund Advisers’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$580K	Buy	12,509 +7,502	+150%	+$368K	0.01%	319
2017 Q3	$267K	Sell	5,007 -311	-6%	-$18.4K	﹤0.01%	355
2017 Q2	$340K	Sell	5,318 -158	-3%	-$9.52K	﹤0.01%	358
2017 Q1	$371K	Sell	5,476 -353	-6%	-$26.9K	﹤0.01%	358
2016 Q4	$410K	Hold	5,829	–	–	﹤0.01%	358
2016 Q3	$414K	Hold	5,829	–	–	﹤0.01%	361
2016 Q2	$301K	Hold	5,829	–	–	﹤0.01%	378
2016 Q1	$369K	Sell	5,829 -1,282	-18%	-$83.9K	﹤0.01%	370
2015 Q4	$798K	Buy	7,111 +1,810	+34%	+$181K	0.01%	304
2015 Q3	$511K	Buy	+5,301	New	+$607K	﹤0.01%	343
2014 Q3	–	Sell	-567	Closed	-$25K	–	1753
2014 Q2	$25K	Buy	+567	New	+$23.3K	﹤0.01%	2305

Other funds holding RARE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Virtus Fund Advisers's RARE Position: Q4 2017 in Review

Virtus Fund Advisers increased its Ultragenyx Pharmaceutical (RARE) stake by 150% in Q4 2017, buying an estimated $368K and bringing the position to 12,509 shares worth $580K. The position accounts for 0.01% of the portfolio, ranked #319.

Virtus Fund Advisers first reported a position in RARE in Q2 2014 and has held it in 11 quarters since. The position peaked at $798K in Q4 2015. 163 funds tracked by Wall St. Rank hold RARE as of Q4 2017.

Virtus Fund Advisers held 12,509 shares of Ultragenyx Pharmaceutical worth $580K as of Q4 2017.
Virtus Fund Advisers bought 7,502 Ultragenyx Pharmaceutical shares in Q4 2017, an estimated $368K.
Ultragenyx Pharmaceutical made up 0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #319 holding.
Virtus Fund Advisers first reported a position in Ultragenyx Pharmaceutical in Q2 2014 and has held it in 11 quarters since.
Virtus Fund Advisers's Ultragenyx Pharmaceutical position peaked at $798K in Q4 2015.
163 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.